Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) opened at $6.00 on Tuesday. Tetraphase Pharmaceuticals, Inc. has a 1 year low of $3.57 and a 1 year high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The business’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) earnings per share. equities research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current fiscal year.
Several analysts have commented on the company. ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. HC Wainwright raised their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, November 6th. Finally, BMO Capital Markets raised their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $15.15.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
What are top analysts saying about Tetraphase Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals Inc. and related companies.